MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.

The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention with cardiac resynchronization therapy plus defibrillator in patients with electrical block pattern of complete left bundle branch was associated with a significant reduction of events in a mean follow-up of 2.4 years compared with the defibrillation therapy only.In this study the effect on long-term survival (mean 5.6 years) of the MADIT -CRT populationwas evaluated.At follow-up end, the rate of death from any cause in patients receiving cardiac resynchronization therapy and defibrillation was 18% versus 29% of those randomized to defibrillation alone (p <0.001).Resynchronization therapy was not associated with any clinical benefit or harm even in patients without LBBB.

Conclusion

In patients with mild symptoms of heart failure, ventricular dysfunction and complete left bundle branch block, early intervention with cardiac resynchronization therapy plus defibrillation is associated with a significant survival benefit in the long term.

Article

6_ilan_goldenberg_slides
Ilan Goldenberg
2014-03-31

Original title: Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure.

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...